Michael Eric LloydSenior Principal Biologist at Eli Lilly and CompanySpeaker
Profile
Michael Lloyd joined Eli Lilly and Company in 2014 leading upstream process development efforts for multiple CHO based biotherapeutics. He has also made extensive contributions to the cell line development platform to increase protein expression, introduce automated workflows, shorten project times, and assess cell line stability. Recently, Michael has supported new therapeutic modalities in genetic medicine portfolio.